Novartis acquisition of Morphosys receives approval from Germany
Published: Tuesday, Mar 12th 2024, 11:30
Updated At: Tuesday, Mar 12th 2024, 11:50
Zurück zu Live Feed
Novartis darf das deutsche Biotech-Unternehmen Morphosys übernehmen. Das deutsche Kartellamt gab am Dienstag grünes Licht für den Kauf.
"We have examined very carefully that competition in the research and development of new drugs against a form of leukemia will not be impaired by the merger. As a result, we have no serious competition concerns," explained Andreas Mundt, President of the German Federal Cartel Office, in a press release.
Novartis hat Anfang Februar seine Absicht bekannt gegeben, Morphosys zu kaufen und beabsichtigt, 68,00 Euro pro Aktie zu zahlen. Damit beläuft sich der Kaufpreis auf 2,7 Milliarden Euro.
The transaction gives Novartis access to pelabresib, a drug for the treatment of myelofibrosis (MF), a life-threatening chronic disease of the bone marrow. In a recent combination study, the active ingredient led to a reduction in spleen volume and thus achieved the targets set. In the USA, the application for approval from the US Food and Drug Administration (FDA) should be submitted in the second half of 2024 if possible.
©Keystone/SDA
German 
English 
French 
Spanish 
Arabic